Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698174 | 0.91 | TACR1 (0.53) | TACR1KMT2AMAPK1MC4RPABPC1 | |
| SCHEMBL4512262 | 0.86 | TACR1 (0.63) | TACR1KMT2AMC4RP2RX7 | |
| SCHEMBL6318950 | 0.85 | TACR1 (0.54) | TACR1KMT2AMAPK1 | |
| SCHEMBL6318956 | 0.81 | TACR1 (0.54) | TACR1MC4R | |
| SCHEMBL4698179 | 0.81 | YAP1 (0.54) | TACR1KMT2AMC4RP2RX7 | |
| SCHEMBL4703222 | 0.81 | TACR1 (0.57) | TACR1KMT2AMC4R | |
| SCHEMBL4699853 | 0.81 | KMT2A (0.49) | TACR1KMT2AMAPK1MC4RPABPC1 | |
| SCHEMBL4700056 | 0.81 | KMT2A (0.49) | TACR1KMT2AMAPK1MC4RPABPC1 | |
| SCHEMBL4701510 | 0.80 | TACR1 (0.49) | TACR1KMT2AMAPK1MC4RALDH1A1 | |
| SCHEMBL4701845 | 0.78 | TACR1 (0.47) | TACR1KMT2AMAPK1MC4RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | TACR1 48/4885KMT2A 1616/4885MAPK1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.